Nachrichten zur Sage Therapeutics Inc. Aktie

Baird predicts steady growth for SAGE Therapeutics at $15 target By Investing.com

Baird predicts steady growth for SAGE Therapeutics at $15 target…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors Sage Therapeutics, Inc. – SAGE

NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGE

NEW YORK, May 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates

Sage Therapeutics (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression…

Sage Therapeutics, Inc. (SAGE) Q1 2024 Earnings Call Transcript

…

Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success

Regeneron (REGN) and Sage Therapeutics (SAGE) are in focus on regulatory and pipeline updates.…

Earnings call: Agile Therapeutics reports growth amid challenges in Q4 By Investing.com

Earnings call: Agile Therapeutics reports growth amid challenges in Q4…

Agile Therapeutics, Inc. (AGRX) Q4 2023 Earnings Call Transcript

…

Agile Therapeutics Q4 2023 Earnings Preview

…

Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics

HUNTSVILLE, Ala., March 26, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (NYSE American: SER), a clinical-stage biotechnology company developing…

Agile Therapeutics to be delisted from Nasdaq By Investing.com

Agile Therapeutics to be delisted from Nasdaq…

Agile Therapeutics Announces Delisting from Nasdaq

PRINCETON, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”),…

AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results

ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company…

Agile Therapeutics clears debt with Perceptive Advisors By Investing.com

Agile Therapeutics clears debt with Perceptive Advisors…

Agile Therapeutics reduces warrant exercise price By Investing.com

Agile Therapeutics reduces warrant exercise price…

Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds

PRINCETON, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”),…

Sage Therapeutics (SAGE) Q4 Earnings & Revenues Beat Estimates

Sage Therapeutics (SAGE) earnings and revenues surpass estimates in the fourth quarter of 2023. Focus on newly launched PPD drug,…

SAGE Therapeutics, Inc. (SAGE) Q4 2023 Earnings Call Transcript

…

Sage Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation

…

Sizing Up Sage Therapeutics

…

Sage Therapeutics: Postpartum Pioneer Or Fiscal Folly, Zurzuvae Dilemma

…

Agile Therapeutics, Inc. (AGRX) Q3 2023 Earnings Call Transcript

…

Agile Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation

…

Agile Therapeutics Q3 2023 Earnings Preview

…

Sage Therapeutics (SAGE) Q3 Earnings Lag Estimates, Down 5%

Sage Therapeutics (SAGE) reports dismal third-quarter results. It intends to price the recently approved oral postpartum depression pill Zurzuvae at…

SAGE Therapeutics, Inc. (SAGE) Q3 2023 Earnings Call Transcript

…

Sage Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation

…

Sage Therapeutics Q3 2023 Earnings Preview

…

Sages (SAGE) Huntingtons Disease Drug Gets FDAs Orphan Tag

The FDA grants orphan drug designation to Sage Therapeutics (SAGE) SAGE-718 for treating Huntingtons disease. The designation will help incentivize…

Sage Therapeutics: Several Neuropsychiatric Disorder Data Readouts In 2024

…

Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today…

Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month?

The pharmaceutical companys growth prospects have taken a big hit....…

Insiderhandel: Aufsichtsrat kauft Aktien von Sage Therapeutic im Wert von 37.279$

Barrett, Elizabeth - Aufsichtsrat - Tag der Transaktion: 2023-08-09...…

Why Shares of Sage Therapeutics Slumped This Week

The company got bad news from the FDA and saw increased losses....…

Is Sage Therapeutics a Contrarian Buy?

A regulatory setback weighed heavily on the drugmakers shares Monday....…

XFRA : SG7: Wiederaufnahme/Resumption

FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING…

Why Sage Therapeutics Stock Is Crashing Today

Sages regulatory win wasnt enough to offset an even bigger regulatory loss....…

Sage Therapeutics stock plunges 48% after FDA decision on postpartum depression drug

The FDA approved the pill Zuranolone, developed by Sage and Biogen, for postpartum depression but declined to approve it for…

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Misses Revenue Estimates

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -5.93% and 15.19%, respectively, for the quarter ended June 2023.…

Sage Therapeutics Shares Slide Premarket After Zurzuvae MDD Setback >SAGE

Sage Therapeutics Shares Slide Premarket After Zurzuvae MDD Setback >SAGE...…

Form 10-Q Sage Therapeutics, Inc. For: Jun 30

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Sage Therapeutics Mulls Job, Pipeline Cuts After FDA Decision >SAGE

Sage Therapeutics Mulls Job, Pipeline Cuts After FDA Decision >SAGE...…

Form 8-K Sage Therapeutics, Inc. For: Aug 07

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Sage Therapeutics GAAP EPS of -$2.68 misses by $0.11, revenue of $2.47M misses by $0.44M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

XFRA : SG7: Aussetzung/Suspension

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME …

XFRA : INSTRUMENT_SUSPENSION - US78667J1088

Instrument ID [10593] (SG7 - US78667J1088) suspended...…

CORRECT: Biogens, Sage Therapeutics postpartum depression drug okayed

Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…

Biogens, Sage Therapeutics postpartum depression treatment approved

Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…

UPDATE 1-US FDA approves Biogen-Sage Therapeutics pill for postpartum depression

...(Adds context throughout) Aug 4 (Reuters) - The U.S. Food and Drug......…

US FDA approves Biogen-Sage Therapeutics pill for clinical depression

...Aug 4 (Reuters) - The U.S. Food and Drug Administration on Friday......…